COVID-19 (Coronavirus)

Interstitial Lung Disease Clinical Trials

If you have idiopathic pulmonary fibrosis (IPF) or any other type of interstitial lung disease (ILD), you may qualify to participate in clinical trials conducted at Cedars-Sinai. By participating in clinical trials, you will have access to the latest medical and surgical techniques, backed by a respected team of specialists and researchers who have helped develop some of the latest treatments for ILD now used around the world.

Questions? See the Clinical Trials FAQs.

Condition: Idiopathic pulmonary fibrosis

Participant Requirements:

  • ≥40 years old
  • Diagnosed with IPF within four years of screening
  • Diagnosis of IPF is supported by HRCT and historical surgical lung biopsy

Summary:

The purpose of this study is to determine the effects of an investigational drug called CC-90001 on patients diagnosed with idiopathic pulmonary fibrosis (IPF), a condition in which scarring of the lungs occurs.

Condition: Idiopathic pulmonary fibrosis

Key Inclusion Criteria:

  • Between 40 and 80 years old
  • Diagnosis of idiopathic pulmonary fibrosis (IPF) within 5 years

Summary:

This study focuses on individuals who have idiopathic pulmonary fibrosis (IPF) and are between 40 and 80 years old. The purpose of the study is to evaluate the safety of an experimental medication called ND‑L02‑s0201 when administered at two dose levels compared with placebo (inactive substance).

ND-L02-s0201 is made up of tiny particles of fat that also contain a small amount of RNA (ribonucleic acid) that is the active drug. The RNA in ND-L02-s0201 is designed to block the lungs from making a protein called "heat shock protein 47" (HSP47) for a limited period of time. It is thought that blocking the lungs from making HSP47 will help treat IPF because one of the roles of HSP47 is to help make collagen, which is involved in fibrosis (scarring).

Participation in the study will be approximately 40 weeks, including a screening and baseline period of up to 6 weeks, a treatment period of 24 weeks and a follow-up period of 10 weeks. Participants will attend 16-17 on-site visits at Cedars-Sinai and will receive an IV study drug infusion every 2 weeks at Cedars-Sinai during the treatment period.

Condition: Idiopathic pulmonary fibrosis

Key Inclusion Criteria:

  • Between 40 and 80 years old
  • Women of childbearing potential and all male participants must agree to use contraception
  • Features consistent with idiopathic pulmonary fibrosis (IPF) within 5 years prior to screening

Summary:

The purpose of this study is to evaluate the safety and tolerability of an experimental drug called TRK-250 after single and multiple inhaled doses in patients with idiopathic pulmonary fibrosis (IPF). TRK-250 is intended to inhibit the messages in the cell that create a protein involved in lung fibrosis (scarring). This study will be conducted in two parts, single inhaled dose (Part A) and multiple inhaled doses (Part B). Subjects in both parts will be randomly assigned to receive either TRK-250 or placebo (inactive substance).